A trial in China could cost half of what it does in the U.S., says the report. With clinical trials accounting for up to two-thirds of the cost of drug development, savings could be substantial.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil, and the Czech Republic followed behind China.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil, and the Czech Republic followed behind China.
